| abstract |
Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and uses thereof Summary Multi-specific binding proteins that bind to and kill cancer cells expressing CD33 (Siglec-3), as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer expressing CD33 are disclosed. The present invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33 and exhibit high potency and maximum potency of target cells when compared to anti-CD33 monoclonal antibodies. |